The Somatostatin In The Treatment Of Moderate To Severe Acute Pancreatitis:A Meta-analysis

Background: The management of acute pancreatitis(AP) is still based on speculative and unproven paradigms in many centers. Therefore, we performed an evidence-based analysis to assess the best available treatment.Object:To systematically evaluate the effect and safety of somatostatin on moderate to severe acute pancreatitis.Methodology:The Cochrane Central Register of Controlled Trials(CENTRAL) in The Cochrane Library, PubMed(1975-2014), CNKI(1994-2014), and Chinese Biomedicine Database(CBM) were search-ed in September 2014,wanfang database,weipu database.with chosed randomized cont-rolled trials.Major outcomes contained mortality, incidence rate of complications, rate of surgical intervention, and length of hospital stay. RevMan 5.3 was performed evaluating the value of somatostatin treatment. Each study was ranked according to the evidence-based methodology; whenever feasible, we performed new meta-analyses using the fix- effects model.Results: Seventeen randomized clinical trials with 1085 participants were included and evaluated.The complication rate and surgical intervention rate of somatosta-tin treating group was obviously less than that of the control group. Somatostatin could decrease the mortality of moderate to severe acute pancreatitis, shorten the hospital stays.Conclusions: Present evidence approve somatostatin’s benefit in the major outcomes of moderate to severe acute pancreatitis and further randomized controlled trials with high quality and large sample size are required.